Dominant Companies in the Taiwan Colorectal Cancer Market | Insights 2026

Q: How is the Taiwan market different from other Southeast Asian markets?

The market is characterized by its universal National Health Insurance system, which provides a standardized approach to screenings and treatments.

Q: How does National Health Insurance (NHI) contribute to the growth of the market?

The NHI is the key source of accessibility, and its reimbursement of innovative cancer therapies determines the speed and extent of the global pharmaceutical companies’ new treatments.

Q: What is the response of global companies to the high demand for personalized medicine?

Companies are increasingly adopting Value-Based Healthcare models, in which they partner with local hospitals to provide real-world evidence and patient-support services.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA12897

Publication Date: Jun 2026

Dominant Companies in the Taiwan Colorectal Cancer Market

The Taiwan Colorectal Cancer Market is characterized by strong integration of advanced medical technology, along with highly efficient government backed healthcare system. Colorectal cancer is one of the most prevalent malignancies in Taiwan, and global pharmaceutical manufacturers play a pivotal role in introducing precision medicine and high-efficacy therapies. These companies are increasingly collaborating with the National Health Insurance (NHI) system and leading medical centres, to ensure that patients have convenient access to diagnostic innovation and specialized cancer treatments.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Taiwan Colorectal Cancer Market.

View Main Report Schedule Analyst Call

Taiwan Colorectal Cancer Market

According to 6Wresearch, the Taiwan colorectal cancer market is marked by a sophisticated diagnostic infrastructure, which is significantly supplemented by high frequency screening programs. Taiwan has a systematic approach to early detection, with nationwide faecal immunochemical testing (FIT), and standardized colonoscopy protocols.

The healthcare landscape is being shaped by value-based oncology, with market leaders aligning portfolios to the reimbursement needs of the NHI. Moreover, strategic partnerships between multinational enterprises and local medical research institutions are driving the shift towards a precision-medicine-led ecosystem, with an aim to improve survival rates for the metastatic stages of the disease.

Competitive Landscape

The competitive landscape of the Taiwan colorectal cancer industry is a multinational corporation-led industry, emphasizing clinical trial participation and evidence-based medicine. Major players are deeply embedded in the local oncology care field, offering patient support programs and digital health tools, to improve treatment adherence and monitoring.

List of leading players currently operating in the Taiwan Colorectal Cancer Market:

1. Roche (Taiwan) Co., Ltd.

Company Name	Roche (Taiwan) Co., Ltd.
Established Year	1896
Headquarters	Basel, Switzerland
Official Website	Click Here

Roche leads with an extensive portfolio of advanced diagnostics and targeted biological therapies essential for molecular-based colorectal cancer treatment.

2. Merck Ltd. (Taiwan)

Company Name	Merck Ltd. (Taiwan)
Established Year	1668
Headquarters	Darmstadt, Germany
Official Website	Click Here

Merck provides critical monoclonal antibodies and innovative oncology products integrated into the standard care protocols for advanced colorectal cancer.

3. Bristol Myers Squibb (BMS) Taiwan

Company Name	Bristol Myers Squibb (BMS) Taiwan
Established Year	1887
Headquarters	New York, New York, United States
Official Website	Click Here

BMS is a cornerstone of the oncology sector, offering high-efficacy immuno-oncology treatments that have significantly improved outcomes for patients.

4. Eli Lilly and Company (Taiwan), Inc.

Company Name	Eli Lilly and Company (Taiwan), Inc.
Established Year	1876
Headquarters	Indianapolis, Indiana, United States
Official Website	Click Here

Lilly supports the market by supplying foundational anti-cancer therapies that are vital for multi-line treatment regimens.

5. Amgen Taiwan Limited

Company Name	Amgen Taiwan Limited
Established Year	1980
Headquarters	Thousand Oaks, California, United States
Official Website	Click Here

Amgen utilizes its biotechnology leadership to provide targeted therapies and precision medicine solutions tailored for complex gastrointestinal cancer cases.

6. Sanofi Taiwan Co., Ltd.

Company Name	Sanofi Taiwan Co., Ltd.
Established Year	1973
Headquarters	Paris, France
Official Website	Click Here

Sanofi maintains a robust presence by supplying essential chemotherapeutic agents and fostering innovation in long-term oncology care management.

7. Bayer Taiwan Co., Ltd.

Company Name	Bayer Taiwan Co., Ltd.
Established Year	1863
Headquarters	Leverkusen, Germany
Official Website	Click Here

Bayer specializes in advanced therapeutic options, including multi-kinase inhibitors, providing critical secondary treatment alternatives for patients.

8. Pfizer Limited (Taiwan)

Company Name	Pfizer Limited (Taiwan)
Established Year	1849
Headquarters	New York, New York, United States
Official Website	Click Here

Pfizer is highly active in the Taiwan market, focusing on the supply of targeted biologics and small molecules specifically designed for gastrointestinal oncology.